drugset
drugset / Trial / NCT06930872

Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates

NCT06930872 ↗

Phase 1 Completed 29 enrolled Harmony Biosciences Management, Inc.
Non-randomizedSequentialOpen-labelOther

Summary

This study is an open-label drug-drug interaction (DDI) study of ZYN002 transdermal gel and multiple drugs.

Timeline

Start
2025-06-06
Primary completion
2025-10-04
Completion
2025-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule — Oral
Subject Caffeine Small molecule — Oral
Subject Dextromethorphan Unknown — Oral
Subject Losartan Other / unclassified — Oral
Subject Midazolam Small molecule — Oral
Subject Omeprazole Other / unclassified — Oral
Subject Repaglinide Small molecule — Oral
Subject Valproate Small molecule — Oral
Subject ZYN002 Unknown — Other

Indications

No indication recorded.